By Scrying Biotech : Chronic pain suppression in the U.S. is a $13B market annually whose landscape is constantly changing based upon the unintended consequences of drug addiction. The most popular of these opiates is Purdue's OxyContin, ranked 18th in total U.S. sales last year at $2.46B. Sales of
develop broad pipelines have fared a little better. Nektar Therapeutics (NASDAQ: NKTR ) belongs on that list, as the company continues ..... Nektar's PEGylated naloxol (also known as NKTR -118) has less than a month to go before it should
By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...
bromide) for treatment of opioid-induced constipation. Salix successfully appealed a CRL that the agency issued on July 27, 2012. Related tickers: (NASDAQ: PGNX ) (NASDAQ: NKTR ) (NYSE: AZN ) (NASDAQ: CBST ) Post your comment!
By Scrying Biotech: Nektar (NASDAQ: NKTR ) Therapeutics of San Francisco has been a hybrid commercial and developmental-stage biotechnology company for many years now
By Scrying Biotech : If you read my article last week entitled, Nektar: Reason Will Rarely Fail You and carefully considered what it is I told you, then you no doubt have already been rewarded for having done so. A pullback in the value of Nektar shares was disproportionately steep and wise ...
Nektar Therapeutics (NASDAQ: NKTR ) Q2 2014 Earnings Conference Call July 31, 2014 5:00 PM ET Executives ..... Operator Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Second Quarter 2014 Financial Results Conference Call. At
year for biotechnology investing! Even stocks that scream "sure bet" and "buy now" are getting reamed. Nektar (NASDAQ: NKTR ) is no exception. My biotech portfolio is all paper red and I'm embarrassed. I'm hoping for a big turnaround, but realistically
bowel movements during Week 4 of the Treatment Period. Synergy intends to release top-line data from the trial in Q4. Related tickers: ( NKTR -5.2% ) ( AZN -2.1% ) ( CBST -0.8% ) ( SLXP -1.6% ) ( PGNX ) Post your comment!
(Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.